The aromatase inhibitors
are the new expansion in the hormonal treatment of breast cancer.
Toxicity of the aromatase inhibitor
letrozole to Japanese medaka (Oryzias latipes) eggs, larvae and breeding adults.
Comparision of two aromatase inhibitors
in women with Clomiphene resistant polycystic ovary syndrome.
[9.] Singh R, Singh AK, Madhu Tripathi (2012) Effect of an aromatase inhibitor
analogue tamoxifen on the gonad and sex differentiation in Nile tilapia Oreochromis niloticus.
(ii) Studies that addressed the association between the third-generation bisphosphonates with aromatase inhibitor
in breast cancer treatment,
Masculinization of female golden rabbitfish Siganus guttatus using an aromatase inhibitor
treatment during sex differentiation.
Bone mineral density decreased over time in the exemestane group; however, patients on the aromatase inhibitor
had no increased risk of fractures.
Use of aromatase inhibitors
to treat endometriosis-related pain symptoms: a systematic review.
Thus, hormonal agents have been evaluated as potential treatments for advanced stage or recurrent adult granulosa cell tumours.2,6,7 Recently several published reports have indicated the possible use of hormonal therapy in the management of recurrent chemoresistent or progressive non-responding granulose-theca cell tumours, including medroxyprogesterone acetate, GnRH agonists, and megestrol (Megace).8 Aromatase inhibitor
Anastrozole, which inhibit the conversion of androstenedione to estrone, is described recently in the management of GCT patients who previously received surgery and chemotherapy.6,7,9
Arimidex: a potent and selective fourth-generation aromatase inhibitor
. Breast Cancer Res Treat 1994;30:103-11.
Exemestane, a different kind of drug called an aromatase inhibitor
, lessens the amount of estrogen made in the body.
Not all breast cancer patients are eligible to take tamoxifen or aromatase inhibitors
, but for some patients with estrogen-sensitive tumors, doctors are now prescribing both drugs, a five-year course of tamoxifen followed by a five-year course of an aromatase inhibitor